tegafur has been researched along with Carcinoma, Anaplastic in 89 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "With a view to improving treatment response and the quality of life of cancer patients, this study investigated the clinical efficacy of combining lentinan, a flavonoid compound with antitumor abilities, with traditional chemotherapy in individuals with esophageal carcinoma (EC), with a particular focus on its effect on immune function." | 9.16 | Combination therapy with lentinan improves outcomes in patients with esophageal carcinoma. ( Bi, Z; Gu, XM; Wang, JL; Zou, JW, 2012) |
| "This study evaluated long-term outcomes for patients who received adjuvant gemcitabine plus S-1 chemotherapy after resection for pancreatic carcinoma." | 9.16 | Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma. ( Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Nakashima, A; Sudo, T; Sueda, T; Uemura, K, 2012) |
| "The authors conclude that epirubicin, cisplatin, and oral UFT plus leucovorin, a convenient regimen, has a significant activity and tolerable toxicities in patients with gastric carcinoma." | 9.09 | Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. ( Hyun, JH; Jeen, YT; Kim, BS; Kim, CS; Kim, JS; Kim, YH; Mok, YJ; Shin, SW; Yoon, SY, 2001) |
| "This is an open-label, nonrandomized phase I trial to determine the safety and maximum tolerated dose of irinotecan with a fixed dose of UFT plus oral leucovorin in patients with advanced or metastatic colorectal cancer." | 9.09 | UFT/leucovorin plus weekly irinotecan in advanced or metastatic colorectal cancer. ( Hegewisch-Becker, S; Hossfeld, DK; Lipp, R; Schilling, G, 2000) |
| "The results of this study show that an all-oral regimen of tegafur and leucovorin can obtain biochemical modulation, with a significant response rate, in patients with advanced colorectal carcinoma." | 9.08 | Protracted treatment with tegafur and low dose oral leucovorin in patients with advanced colorectal carcinoma. ( Antón, I; Arcusa, A; Batiste-Alentorn, E; Boleda, M; Nogué, M; Saigí, E; Seguí, MA, 1998) |
| "Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma." | 9.08 | Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; García-Alfonso, P; García-Girón, C; Garrido, P; Gómez-Navarro, J; González Barón, M; Ordónez, A; Zamora, P, 1996) |
| "A randomized study was performed in 35 centers in the Kinki area of Japan to determine the effectiveness of ftrorafur (FT) plus tamoxifen (TAM) compared with FT monotherapy in postoperative adjuvant therapy for breast cancer." | 9.08 | A randomized trial comparing ftorafur alone with ftorafur plus tamoxifen in postoperative adjuvant therapy for breast cancer. Kinki Area Research Group for Postoperative Adjuvant Therapy for Breast Cancer. ( Kosaki, G; Koyama, H; Nakao, K; Oshima, A; Sakai, K; Seno, T; Taguchi, T; Terasawa, T, 1996) |
| "We performed a randomized controlled study of postoperative adjuvant immunochemotherapy with Nocardia rubra cell wall skeleton (N-CWS) and Tegafur for gastric carcinoma between September 1979 and March 1983." | 9.06 | Randomized controlled study of postoperative adjuvant immunochemotherapy with Nocardia rubra cell wall skeleton (N-CWS) and Tegafur for gastric carcinoma. ( Iwasaki, Y; Kawasaki, T; Koyama, S; Osuga, T; Ozaki, A; Sakita, T; Soma, T; Suzuki, M; Tabuchi, T; Watanabe, A, 1986) |
| "In the current study, we have evaluated the clinical and immunological responses in patients with advanced pancreatic carcinoma who received dendritic cell (DC)-based immunotherapy in combination with gemcitabine and/or S-1." | 7.78 | Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. ( Homma, S; Imai, K; Kimura, Y; Koido, S; Okamoto, M; Shimamura, K; Shimodaira, S; Sunamura, M; Takahashi, H; Tomoda, T; Tsukada, J; Yonemitsu, Y, 2012) |
| "Adjuvant gemcitabine plus S-1 chemotherapy may be one of several factors contributing to improved outcomes after aggressive surgical resection of advanced biliary carcinoma in recent years." | 7.75 | Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. ( Hashimoto, Y; Hayashidani, Y; Murakami, Y; Nakamura, H; Nakashima, A; Sudo, T; Sueda, T; Uemura, K, 2009) |
| " In a previous study, the authors demonstrated that the combination of uracil and tegafur (UFT) with leucovorin (LV) was active and well tolerated in patients with advanced colorectal carcinoma (ACC)." | 7.69 | Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. ( Colmenarejo, A; de Castro, J; de la Gándara, I; Espinosa, E; Espinosa, J; Feliu, J; Fernández, Y; García Girón, C; González Barón, M; Jalón, JI, 1997) |
| "Effects of N-(6-aminohexyl)-1-naphthalenesulfonamide (W-5) and N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7) on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur, FT) and a mixture of FT and uracil (UFT) were determined in nude mice bearing human ovarian carcinoma (KF cells)." | 7.67 | Adjuvant effects of calmodulin antagonists on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur) and a mixture of ftorafur and uracil (UFT) in nude mice bearing human ovarian carcinomas. ( Iwano, I; Kikuchi, Y; Kita, T; Kizawa, I; Kuki, E; Miyauchi, M; Oomori, K, 1989) |
| "A multicenter randomized trial was performed comparing oral tegafur/gimeracil/oteracil (S-1) and uracil-tegafur/ leucovorin (UFT/LV) as adjuvant therapy for stage III colorectal cancer." | 5.22 | Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer. ( Kaiho, T; Kobayashi, S; Koda, K; Kosugi, C; Maruyama, T; Matsubara, H; Miyauchi, H; Takiguchi, N, 2016) |
| "With a view to improving treatment response and the quality of life of cancer patients, this study investigated the clinical efficacy of combining lentinan, a flavonoid compound with antitumor abilities, with traditional chemotherapy in individuals with esophageal carcinoma (EC), with a particular focus on its effect on immune function." | 5.16 | Combination therapy with lentinan improves outcomes in patients with esophageal carcinoma. ( Bi, Z; Gu, XM; Wang, JL; Zou, JW, 2012) |
| "This study evaluated long-term outcomes for patients who received adjuvant gemcitabine plus S-1 chemotherapy after resection for pancreatic carcinoma." | 5.16 | Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma. ( Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Nakashima, A; Sudo, T; Sueda, T; Uemura, K, 2012) |
| "The authors conclude that epirubicin, cisplatin, and oral UFT plus leucovorin, a convenient regimen, has a significant activity and tolerable toxicities in patients with gastric carcinoma." | 5.09 | Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. ( Hyun, JH; Jeen, YT; Kim, BS; Kim, CS; Kim, JS; Kim, YH; Mok, YJ; Shin, SW; Yoon, SY, 2001) |
| "This is an open-label, nonrandomized phase I trial to determine the safety and maximum tolerated dose of irinotecan with a fixed dose of UFT plus oral leucovorin in patients with advanced or metastatic colorectal cancer." | 5.09 | UFT/leucovorin plus weekly irinotecan in advanced or metastatic colorectal cancer. ( Hegewisch-Becker, S; Hossfeld, DK; Lipp, R; Schilling, G, 2000) |
| "Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma." | 5.08 | Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; García-Alfonso, P; García-Girón, C; Garrido, P; Gómez-Navarro, J; González Barón, M; Ordónez, A; Zamora, P, 1996) |
| "The results of this study show that an all-oral regimen of tegafur and leucovorin can obtain biochemical modulation, with a significant response rate, in patients with advanced colorectal carcinoma." | 5.08 | Protracted treatment with tegafur and low dose oral leucovorin in patients with advanced colorectal carcinoma. ( Antón, I; Arcusa, A; Batiste-Alentorn, E; Boleda, M; Nogué, M; Saigí, E; Seguí, MA, 1998) |
| "Thirty-nine patients with locally advanced or metastatic gastric carcinoma received oral UFT (tegafur and uracil) plus leucovorin." | 5.08 | A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma. ( Kim, BS; Kim, JG; Kim, JS; Kim, YH; Park, YT; Shin, SW, 1997) |
| "The activity and toxicity of UFT (Tegafur and Uracil) in a 4:1 molar concentration, plus leucovorin (LV), were evaluated in the treatment of 45 patients with advanced, bidimensionally measurable metastatic colorectal carcinoma." | 5.08 | Phase II study of UFT plus leucovorin in colorectal cancer. ( Pazdur, R, 1997) |
| "A randomized study was performed in 35 centers in the Kinki area of Japan to determine the effectiveness of ftrorafur (FT) plus tamoxifen (TAM) compared with FT monotherapy in postoperative adjuvant therapy for breast cancer." | 5.08 | A randomized trial comparing ftorafur alone with ftorafur plus tamoxifen in postoperative adjuvant therapy for breast cancer. Kinki Area Research Group for Postoperative Adjuvant Therapy for Breast Cancer. ( Kosaki, G; Koyama, H; Nakao, K; Oshima, A; Sakai, K; Seno, T; Taguchi, T; Terasawa, T, 1996) |
| "We performed a randomized controlled study of postoperative adjuvant immunochemotherapy with Nocardia rubra cell wall skeleton (N-CWS) and Tegafur for gastric carcinoma between September 1979 and March 1983." | 5.06 | Randomized controlled study of postoperative adjuvant immunochemotherapy with Nocardia rubra cell wall skeleton (N-CWS) and Tegafur for gastric carcinoma. ( Iwasaki, Y; Kawasaki, T; Koyama, S; Osuga, T; Ozaki, A; Sakita, T; Soma, T; Suzuki, M; Tabuchi, T; Watanabe, A, 1986) |
| "We examined the completion rate, safety, and adverse events in patients with T2N0 glottic carcinoma who received chemoradiotherapy with S-1 (tegafur-gimeracil-oteracil potassium)." | 3.80 | Radiotherapy concurrent with S-1 and radiotherapy alone for T2N0 glottic carcinoma: a retrospective comparative study. ( Higashino, M; Ichihara, S; Kawata, R; Lee, K; Nishikawa, S; Uesugi, Y, 2014) |
| "In the current study, we have evaluated the clinical and immunological responses in patients with advanced pancreatic carcinoma who received dendritic cell (DC)-based immunotherapy in combination with gemcitabine and/or S-1." | 3.78 | Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. ( Homma, S; Imai, K; Kimura, Y; Koido, S; Okamoto, M; Shimamura, K; Shimodaira, S; Sunamura, M; Takahashi, H; Tomoda, T; Tsukada, J; Yonemitsu, Y, 2012) |
| "Adjuvant gemcitabine plus S-1 chemotherapy may be one of several factors contributing to improved outcomes after aggressive surgical resection of advanced biliary carcinoma in recent years." | 3.75 | Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. ( Hashimoto, Y; Hayashidani, Y; Murakami, Y; Nakamura, H; Nakashima, A; Sudo, T; Sueda, T; Uemura, K, 2009) |
| " Using a murine dorsal air sac (DAS) assay, we have previously shown that UFT and its metabolites, gamma-hydroxybutyric acid (GHB) and 5-fluorouracil (5-FU), inhibited the angiogenesis induced by murine renal cell carcinoma." | 3.71 | gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. ( Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K, 2001) |
| " In a previous study, the authors demonstrated that the combination of uracil and tegafur (UFT) with leucovorin (LV) was active and well tolerated in patients with advanced colorectal carcinoma (ACC)." | 3.69 | Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. ( Colmenarejo, A; de Castro, J; de la Gándara, I; Espinosa, E; Espinosa, J; Feliu, J; Fernández, Y; García Girón, C; González Barón, M; Jalón, JI, 1997) |
| "Eighty-nine patients with advanced gastric carcinoma were treated with a combination chemo-immunotherapy regimen that consisted of active immunotherapy with Vibrio cholerae neuraminidase (VCN) treated autologous tumor cells admixed with BCG and drugs including cyclophosphamide, mitomycin C (MMC) and 5-fluorouracil, followed by long term tegafur (FT) and immunomodulators." | 3.67 | Combination chemoimmunotherapy for advanced gastric carcinoma. ( Akiyoshi, T; Arinaga, S; Kawaguchi, M; Koba, F; Miyazaki, S; Tsuji, H; Wada, T, 1984) |
| "Effects of N-(6-aminohexyl)-1-naphthalenesulfonamide (W-5) and N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7) on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur, FT) and a mixture of FT and uracil (UFT) were determined in nude mice bearing human ovarian carcinoma (KF cells)." | 3.67 | Adjuvant effects of calmodulin antagonists on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur) and a mixture of ftorafur and uracil (UFT) in nude mice bearing human ovarian carcinomas. ( Iwano, I; Kikuchi, Y; Kita, T; Kizawa, I; Kuki, E; Miyauchi, M; Oomori, K, 1989) |
| " The antitumor activity of this compound was superior to those of 5-FU and 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur, Ftorafur) in the treatment of transplantable tumors, not only 5-FU-sensitive tumors such as adenocarcinoma 755, lymphosarcoma LS-1, and plasmacytoma X5563, but also 5-FU-resistant tumors such as Lewis lung carcinoma and Walker carcinosarcoma 256." | 3.66 | Antitumor activity of methyl (5-fluoro-1H-2-oxo-4-pyrimidinyl beta-D-glucopyranosid)uronate against various experimental tumors. ( Arakawa, M; Inomata, T; Sasagawa, K; Shimizu, F; Shinkai, K, 1981) |
| "Irinotecan was administered intravenously over the course of 90 minutes on day 1, and S-1 was given orally in 2 divided doses from days 1 to 14 of a 21-day cycle." | 2.82 | Phase I Clinical Study of Irinotecan Plus S-1 in Patients With Advanced or Recurrent Cervical Cancer Previously Treated With Platinum-Based Chemotherapy. ( Kimura, T; Kobayashi, E; Kozasa, K; Mabuchi, S; Owa, T; Tomimatsu, T; Tsutui, T; Yamashita, M; Yoki, T; Yokoi, E, 2016) |
| "The response rate of S-1 for colorectal cancer is high, ranging from 35% to 40%." | 2.75 | Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. ( Boku, N; Furuhata, T; Hyodo, I; Kato, T; Koizumi, W; Miyashita, K; Miyata, Y; Nishina, T; Okada, Y; Sawaki, A; Toh, Y; Yamaguchi, K, 2010) |
| " GEM was administrated at a dosage of 1 g/m(2) intravenously weekly 3 of 4 weeks and UFT at a dosage of 200 mg/day orally continuously." | 2.73 | A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer. ( Furukawa, K; Ito, H; Kato, A; Kimura, F; Miyazaki, M; Nozawa, S; Otsuka, M; Shimizu, H; Togawa, A; Yoshidome, H; Yoshitomi, H, 2008) |
| "Distant metastases rate (DMR) was significantly reduced with CRT (14." | 2.71 | Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. ( Au, GK; Chan, RT; Cheng, AC; Choy, DD; Chua, DT; Kwok, CC; Kwong, DL; Kwong, PW; Law, MW; Sham, JS; Wan, KY; Wu, PM; Yau, CC, 2004) |
| "No effective treatment for advanced esophageal cancer extending to adjacent organs or associated with distant metastasis is known." | 2.71 | Concurrent chemoradiotherapy for locally advanced and metastatic esophageal cancer: longterm results of a phase II study of UFT/CDDP with radiotherapy. ( Horiuchi, Y; Indo, T; Iwase, H; Iyo, T; Kaida, S; Kato, E; Kusugami, K; Nakamura, M; Nakarai, K; Shimada, M, 2003) |
| "The main toxicity was diarrhea and oral mucositis." | 2.68 | Phase II trial of Oral UFT and leucovorin in advanced gastric carcinoma. ( Cheong, SK; Kim, JS; Kim, YH; Lee, JD; Park, JS; Shin, SW, 1996) |
| "G-CSF producing anaplastic carcinoma of the pancreas is extremely rare and there are no reports with regard to response evaluation by FDG-PET." | 2.49 | [An autopsy of G-CSF-producing anaplastic carcinoma of the pancreas with impaired accumulation on FDG-PET after S-1 chemotherapy]. ( Ikeda, S; Ito, T; Kanazawa, H; Katada, N; Morita, K; Narita, M; Nishimura, D; Okubo, K; Shibahara, H; Takeuchi, A, 2013) |
| "We diagnosed advanced gastric cancer with disseminated carcinomatosis of the bone marrow and multiple bone metastasis." | 2.47 | [A very elderly case of advanced gastric cancer with disseminated carcinomatosis of bone marrow and multiple bone metastasis, diagnosed by extremely elevated serum alkaline phosphatase levels, and treated with low-dose S-1 to avoid disseminated intravascu ( Ashida, C; Higashida, A; Kawara, F; Kondo, T; Mamori, S; Okutani, T; Onishi, K; Takeda, A; Yamada, H, 2011) |
| "S-1 monotherapy is considered a safe and effective treatment option for recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy." | 1.40 | Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis. ( Chen, ZB; Cheng, H; Lin, Z; Liu, YM; Ou, XQ; Peng, PJ; Tang, YN; Wang, SY; Wu, X; Zeng, LJ; Zhang, HY, 2014) |
| "Prognosis of patients with metastatic gastric cancer is abysmal, usually just a few months." | 1.40 | [Case report of a patient with advanced and disseminated gastric carcinoma treated by s-1]. ( Katolická, J; Rotnáglová, S; Vaníček, J, 2014) |
| "We report a case of gastric cancer accompanied by disseminated carcinomatosis of the bone marrow treated with S-1 and cisplatin( CDDP) combination chemotherapy." | 1.39 | [A case of gastric cancer accompanied by disseminated carcinomatosis of the bone marrow successfully controlled by S-1 and cisplatin combination therapy]. ( Amagasa, H; Ami, K; Ando, M; Aoki, N; Arai, K; Fujiya, K; Fukuda, A; Ganno, H; Imai, K; Kamikozuru, H; Nagahama, T; Ohbu, M; Takeuchi, S; Tei, S, 2013) |
| "Twenty-eight patients with advanced gastric cancer underwent gastrectomy without preoperative chemotherapy." | 1.39 | Adjuvant chemotherapy with S-1 followed by docetaxel for gastric cancer and CY1P0 peritoneal metastasis after relatively curative surgery. ( Fujita, I; Kanazawa, Y; Kato, S; Onodera, H; Uchida, E, 2013) |
| "Thymic carcinoma is a rare intrathoracic malignant tumor, and the prognosis for patients with advanced stage of the disease is poor." | 1.36 | S-1 is an active anticancer agent for advanced thymic carcinoma. ( Hosomi, Y; Iguchi, M; Okamura, T; Okuma, Y; Shibuya, M; Shimokawa, T; Takagi, Y, 2010) |
| "We diagnosed disseminated carcinomatosis of bone marrow by gastric cancer." | 1.35 | [A case of advanced gastric cancer with disseminated carcinomatosis of bone marrow treated by S-1 and CDDP]. ( Fujishima, Y; Fukuda, T; Fukunaga, H; Iwai, M; Koide, M; Miura, M; Yoneda, R, 2009) |
| "We report a case of anaplastic carcinoma of the thyroid administered peroral fluorinated pyrimidine, providing longterm survival during three years." | 1.35 | [A case of anaplastic carcinoma of thyroid administered peroral fluorinated pyrimidine for long-term survival during three years]. ( Kira, M; Takizawa, H; Tangoku, A; Toba, H; Yamai, H; Yoshida, T, 2009) |
| " Pharmacokinetic modulating chemotherapy (PMC), a combination of infused 5-fluorouracil and oral uracil-tegafur, has been proven to be highly effective for the treatment of colorectal carcinoma." | 1.32 | Modified pharmacokinetic modulating chemotherapy using 5-fluorouracil, UFT, and taxotere (docetaxel) for advanced gastric cancer. ( Kobayashi, M; Konishi, N; Kusunoki, M; Mohri, Y; Ohmori, Y; Tanaka, K; Tonouchi, H, 2003) |
| " Rats were dosed p." | 1.29 | 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. ( Baccanari, DP; Cao, S; Davis, ST; Joyner, SS; Rustum, YM; Spector, T, 1995) |
| "A 66-year-old woman with left breast cancer (medullary carcinoma; T1cN1M0; Stage II A) was treated with breast conserving therapy combined with lumpectomy, radiotherapy, chemotherapy and endocrine therapy beginning in March, 1990." | 1.28 | [A case report of bone metastasis diagnosed by MRI and effectively treated with UFT after breast conserving therapy for breast cancer]. ( Hamada, N; Inomata, T; Nishioka, A; Ogawa, Y; Ogoshi, S; Sawada, A; Tanaka, Y; Terashima, M, 1992) |
| "A case of right breast and thyroid cancer is reported in which, despite metastasis to the spinal cord occurring 1 year after mastectomy, satisfactory therapeutic results were obtained." | 1.27 | [Complete remission in a case of concurrent breast and thyroid cancers with metastatic spinal paralysis]. ( Kure, M; Niwa, M; Ohganè, T, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (23.60) | 18.7374 |
| 1990's | 15 (16.85) | 18.2507 |
| 2000's | 22 (24.72) | 29.6817 |
| 2010's | 28 (31.46) | 24.3611 |
| 2020's | 3 (3.37) | 2.80 |
| Authors | Studies |
|---|---|
| Itano, O | 1 |
| Takemura, Y | 1 |
| Kishida, N | 1 |
| Tamagawa, E | 1 |
| Shinozaki, H | 1 |
| Ikeda, K | 1 |
| Urakami, H | 1 |
| Ei, S | 1 |
| Hayatsu, S | 1 |
| Suzuki, K | 1 |
| Sakuragawa, T | 1 |
| Ishii, M | 1 |
| Shito, M | 1 |
| Aiura, K | 1 |
| Fujisaki, H | 1 |
| Takano, K | 1 |
| Matsui, J | 1 |
| Minagawa, T | 1 |
| Shinoda, M | 1 |
| Kitago, M | 1 |
| Abe, Y | 1 |
| Yagi, H | 1 |
| Oshima, G | 1 |
| Hori, S | 1 |
| Kitagawa, Y | 2 |
| Imaoka, H | 1 |
| Ikeda, M | 2 |
| Maehara, K | 1 |
| Umemoto, K | 1 |
| Ozaka, M | 1 |
| Kobayashi, S | 2 |
| Terashima, T | 1 |
| Inoue, H | 1 |
| Sakaguchi, C | 1 |
| Tsuji, K | 2 |
| Shioji, K | 1 |
| Okamura, K | 1 |
| Kawamoto, Y | 1 |
| Suzuki, R | 1 |
| Shirakawa, H | 1 |
| Nagano, H | 1 |
| Ueno, M | 1 |
| Morizane, C | 2 |
| Furuse, J | 2 |
| Li, Y | 1 |
| Cui, L | 1 |
| Chen, Y | 1 |
| Wang, F | 1 |
| Doi, T | 1 |
| Sakamoto, T | 1 |
| Okino, T | 1 |
| Ikeda, S | 1 |
| Okubo, K | 1 |
| Shibahara, H | 1 |
| Narita, M | 1 |
| Morita, K | 1 |
| Takeuchi, A | 1 |
| Kanazawa, H | 1 |
| Ito, T | 1 |
| Nishimura, D | 1 |
| Katada, N | 1 |
| Tsuya, A | 1 |
| Kurata, T | 1 |
| Tamiya, A | 1 |
| Okamoto, I | 2 |
| Ueda, S | 1 |
| Sakai, D | 1 |
| Sugimoto, N | 1 |
| Matsumoto, K | 2 |
| Goto, I | 1 |
| Yamamoto, N | 2 |
| Fukuoka, M | 2 |
| Nakagawa, K | 2 |
| Sunaga, T | 1 |
| Suzuki, S | 1 |
| Kogo, M | 1 |
| Kurihara, T | 1 |
| Kaji, S | 1 |
| Koike, N | 1 |
| Harada, N | 1 |
| Suzuki, M | 3 |
| Kiuchi, Y | 1 |
| Kanazawa, Y | 1 |
| Kato, S | 1 |
| Fujita, I | 1 |
| Onodera, H | 1 |
| Uchida, E | 1 |
| Ganno, H | 1 |
| Nagahama, T | 1 |
| Fukuda, A | 1 |
| Takeuchi, S | 2 |
| Fujiya, K | 1 |
| Amagasa, H | 1 |
| Kamikozuru, H | 1 |
| Imai, K | 2 |
| Ami, K | 1 |
| Aoki, N | 2 |
| Ando, M | 1 |
| Arai, K | 1 |
| Tei, S | 1 |
| Ohbu, M | 1 |
| Fujisawa, Y | 1 |
| Fujimoto, M | 1 |
| Higashino, M | 1 |
| Kawata, R | 1 |
| Lee, K | 1 |
| Nishikawa, S | 1 |
| Ichihara, S | 1 |
| Uesugi, Y | 1 |
| Katolická, J | 1 |
| Rotnáglová, S | 1 |
| Vaníček, J | 1 |
| Peng, PJ | 1 |
| Cheng, H | 1 |
| Ou, XQ | 1 |
| Zeng, LJ | 1 |
| Wu, X | 1 |
| Liu, YM | 1 |
| Lin, Z | 1 |
| Tang, YN | 1 |
| Wang, SY | 1 |
| Zhang, HY | 1 |
| Chen, ZB | 1 |
| Murakami, Y | 4 |
| Uemura, K | 4 |
| Sudo, T | 4 |
| Hashimoto, Y | 4 |
| Kondo, N | 3 |
| Nakagawa, N | 2 |
| Sasaki, H | 1 |
| Sueda, T | 4 |
| Yoshida, M | 1 |
| Muro, K | 1 |
| Tsuji, A | 2 |
| Hamamoto, Y | 1 |
| Yoshino, T | 1 |
| Yoshida, K | 1 |
| Shirao, K | 1 |
| Miyata, Y | 2 |
| Takahari, D | 1 |
| Takahashi, T | 2 |
| Ohtsu, A | 1 |
| Hayashi, H | 1 |
| Eguchi, N | 1 |
| Sumimoto, K | 1 |
| Azakami, T | 1 |
| Sumida, T | 1 |
| Tamura, T | 1 |
| Sumii, M | 1 |
| Uraoka, N | 1 |
| Shimamoto, F | 1 |
| Mabuchi, S | 1 |
| Yokoi, E | 1 |
| Owa, T | 1 |
| Kozasa, K | 1 |
| Yamashita, M | 1 |
| Kobayashi, E | 1 |
| Tomimatsu, T | 1 |
| Yoki, T | 1 |
| Tsutui, T | 1 |
| Kimura, T | 2 |
| Koda, K | 1 |
| Miyauchi, H | 1 |
| Kosugi, C | 1 |
| Kaiho, T | 1 |
| Takiguchi, N | 1 |
| Maruyama, T | 2 |
| Matsubara, H | 1 |
| Yoshitomi, H | 1 |
| Togawa, A | 1 |
| Kimura, F | 1 |
| Ito, H | 1 |
| Shimizu, H | 2 |
| Yoshidome, H | 1 |
| Otsuka, M | 1 |
| Kato, A | 1 |
| Nozawa, S | 1 |
| Furukawa, K | 1 |
| Miyazaki, M | 1 |
| Yamai, H | 1 |
| Yoshida, T | 1 |
| Toba, H | 1 |
| Kira, M | 1 |
| Takizawa, H | 1 |
| Tangoku, A | 1 |
| Tanigawa, T | 1 |
| Miyamoto, Y | 1 |
| Abe, M | 1 |
| Hasuo, T | 1 |
| Doiguchi, M | 1 |
| Sakamoto, F | 1 |
| Koizumi, W | 1 |
| Boku, N | 1 |
| Yamaguchi, K | 1 |
| Sawaki, A | 1 |
| Kato, T | 1 |
| Toh, Y | 2 |
| Hyodo, I | 1 |
| Nishina, T | 1 |
| Furuhata, T | 1 |
| Miyashita, K | 1 |
| Okada, Y | 1 |
| Hayashidani, Y | 1 |
| Nakamura, H | 1 |
| Nakashima, A | 3 |
| Fujishima, Y | 1 |
| Yoneda, R | 1 |
| Iwai, M | 1 |
| Fukunaga, H | 1 |
| Miura, M | 1 |
| Koide, M | 1 |
| Fukuda, T | 1 |
| Tanizaki, J | 1 |
| Takezawa, K | 1 |
| Tsukioka, S | 1 |
| Uchida, J | 1 |
| Kiniwa, M | 1 |
| Hashiguchi, K | 1 |
| Kitajima, Y | 1 |
| Kai, K | 1 |
| Hiraki, M | 1 |
| Nakamura, J | 1 |
| Tokunaga, O | 1 |
| Noshiro, H | 1 |
| Miyazaki, K | 1 |
| Yoon, DH | 1 |
| Cho, Y | 1 |
| Kim, SY | 1 |
| Nam, SY | 1 |
| Choi, SH | 1 |
| Roh, JL | 1 |
| Lee, SW | 1 |
| Song, SY | 1 |
| Lee, JH | 1 |
| Kim, JS | 4 |
| Cho, KJ | 1 |
| Kim, SB | 1 |
| Okuma, Y | 1 |
| Shimokawa, T | 1 |
| Takagi, Y | 1 |
| Hosomi, Y | 1 |
| Iguchi, M | 1 |
| Okamura, T | 2 |
| Shibuya, M | 1 |
| Kogashiwa, Y | 1 |
| Yamauchi, K | 1 |
| Nagafuji, H | 1 |
| Matsuda, T | 1 |
| Tsubosaka, T | 1 |
| Karaho, T | 1 |
| Kohno, N | 1 |
| Yabe, N | 1 |
| Murai, S | 1 |
| Akatsu, T | 1 |
| Shoji, T | 1 |
| Fukushima, H | 1 |
| Mitsugi, Y | 1 |
| Ishida, T | 1 |
| Amemiya, T | 1 |
| Hasegawa, H | 2 |
| Kimura, Y | 1 |
| Tsukada, J | 1 |
| Tomoda, T | 1 |
| Takahashi, H | 1 |
| Shimamura, K | 1 |
| Sunamura, M | 1 |
| Yonemitsu, Y | 1 |
| Shimodaira, S | 1 |
| Koido, S | 1 |
| Homma, S | 1 |
| Okamoto, M | 1 |
| Takeda, A | 1 |
| Kawara, F | 1 |
| Onishi, K | 1 |
| Higashida, A | 1 |
| Mamori, S | 1 |
| Ashida, C | 1 |
| Okutani, T | 1 |
| Yamada, H | 1 |
| Kondo, T | 1 |
| Wang, JL | 1 |
| Bi, Z | 1 |
| Zou, JW | 1 |
| Gu, XM | 1 |
| Sakabe, R | 1 |
| Ohge, H | 1 |
| Hiyama, E | 1 |
| Doyama, H | 1 |
| Yamada, S | 1 |
| Kaneko, Y | 1 |
| Takemura, K | 1 |
| Tsuji, S | 1 |
| Tominaga, K | 1 |
| Inagaki, S | 1 |
| Hayashi, T | 1 |
| Ito, R | 1 |
| Nakanishi, H | 2 |
| Kitou, Y | 1 |
| Takeda, Y | 1 |
| Yamamoto, M | 1 |
| Inaki, N | 1 |
| Yamada, T | 1 |
| Niwa, H | 1 |
| Katayanagi, K | 1 |
| Kurumaya, H | 1 |
| Mochizuki, Y | 1 |
| Kodera, Y | 1 |
| Ito, S | 1 |
| Yamamura, Y | 1 |
| Ito, K | 1 |
| Akiyama, S | 1 |
| Nakao, A | 1 |
| Tatematsu, M | 1 |
| Takahashi, K | 1 |
| Miyagawa, K | 1 |
| Mitachi, Y | 2 |
| Masuda, T | 1 |
| Oogoshi, T | 1 |
| Kawami, H | 1 |
| Shigematsu, H | 1 |
| Fujimoto, Y | 1 |
| Iwase, H | 1 |
| Shimada, M | 1 |
| Nakamura, M | 1 |
| Nakarai, K | 1 |
| Iyo, T | 1 |
| Kaida, S | 1 |
| Indo, T | 1 |
| Kato, E | 1 |
| Horiuchi, Y | 1 |
| Kusugami, K | 1 |
| Tanaka, K | 1 |
| Konishi, N | 1 |
| Ohmori, Y | 1 |
| Kobayashi, M | 1 |
| Mohri, Y | 1 |
| Tonouchi, H | 1 |
| Kusunoki, M | 1 |
| Veldhorst-Janssen, NM | 1 |
| Boersma, HH | 1 |
| de Krom, MC | 1 |
| van Rijswijk, RE | 1 |
| Nakayama, A | 1 |
| Ishida, S | 1 |
| Katsuragi, A | 1 |
| Adachi, M | 1 |
| Kwong, DL | 1 |
| Sham, JS | 1 |
| Au, GK | 1 |
| Chua, DT | 1 |
| Kwong, PW | 1 |
| Cheng, AC | 1 |
| Wu, PM | 1 |
| Law, MW | 1 |
| Kwok, CC | 1 |
| Yau, CC | 1 |
| Wan, KY | 1 |
| Chan, RT | 1 |
| Choy, DD | 1 |
| Jentsch-Ullrich, K | 1 |
| Kalinski, T | 1 |
| Roessner, A | 1 |
| Franke, A | 1 |
| Mohren, M | 1 |
| Ishigami, S | 1 |
| Nakajo, A | 1 |
| Uenosono, Y | 1 |
| Okumura, H | 1 |
| Matsumoto, M | 1 |
| Arigami, T | 1 |
| Uchikado, Y | 1 |
| Setoyama, T | 1 |
| Hokita, S | 1 |
| Natsugoe, S | 1 |
| Aikou, T | 1 |
| Okusaka, T | 1 |
| Ito, Y | 1 |
| Ueno, H | 1 |
| Ishii, H | 1 |
| Kawashima, M | 1 |
| Kagami, Y | 1 |
| Ikeda, H | 2 |
| Morita, S | 1 |
| Nakata, B | 1 |
| Shirasaka, T | 1 |
| Saji, S | 1 |
| Ohashi, Y | 1 |
| Sakamoto, J | 1 |
| Hirakawa, K | 1 |
| Kim, YH | 4 |
| Seo, HY | 1 |
| Jeen, YT | 2 |
| Kim, HK | 1 |
| Shim, BY | 1 |
| Yang, J | 1 |
| Fujita, F | 1 |
| Fujita, M | 1 |
| Taguchi, T | 2 |
| Kano, T | 1 |
| Kumashiro, R | 1 |
| Masuda, H | 1 |
| Tamada, R | 1 |
| Inokuchi, K | 1 |
| Akiyoshi, T | 1 |
| Kawaguchi, M | 1 |
| Arinaga, S | 1 |
| Miyazaki, S | 1 |
| Koba, F | 1 |
| Wada, T | 1 |
| Tsuji, H | 1 |
| Grigorova, TM | 1 |
| Vartanian, LG | 1 |
| Marenich, AF | 1 |
| Narisawa, T | 1 |
| Sato, M | 1 |
| Tani, M | 1 |
| Arakawa, M | 1 |
| Shimizu, F | 1 |
| Sasagawa, K | 1 |
| Inomata, T | 2 |
| Shinkai, K | 1 |
| Blokhina, NG | 1 |
| Sorokina, GA | 1 |
| Cao, S | 1 |
| Baccanari, DP | 1 |
| Joyner, SS | 1 |
| Davis, ST | 1 |
| Rustum, YM | 1 |
| Spector, T | 1 |
| Cheong, SK | 1 |
| Lee, JD | 1 |
| Park, JS | 1 |
| Shin, SW | 3 |
| Sakai, K | 1 |
| Kosaki, G | 1 |
| Seno, T | 1 |
| Terasawa, T | 1 |
| Nakao, K | 1 |
| Koyama, H | 1 |
| Oshima, A | 1 |
| Feliu, J | 2 |
| González Barón, M | 2 |
| García-Girón, C | 1 |
| Espinosa, E | 2 |
| García-Alfonso, P | 1 |
| Belón, J | 1 |
| Blanco, E | 1 |
| Garrido, P | 1 |
| Ordónez, A | 1 |
| Gómez-Navarro, J | 1 |
| Zamora, P | 1 |
| Pazdur, R | 2 |
| García Girón, C | 1 |
| de la Gándara, I | 1 |
| Espinosa, J | 1 |
| Colmenarejo, A | 1 |
| Jalón, JI | 1 |
| Fernández, Y | 1 |
| de Castro, J | 1 |
| Kim, BS | 2 |
| Park, YT | 1 |
| Kim, JG | 1 |
| Lassere, Y | 1 |
| Diaz-Canton, E | 1 |
| Ho, DH | 1 |
| Nogué, M | 1 |
| Seguí, MA | 1 |
| Saigí, E | 1 |
| Batiste-Alentorn, E | 1 |
| Arcusa, A | 1 |
| Boleda, M | 1 |
| Antón, I | 1 |
| Oki, E | 1 |
| Sakaguchi, Y | 1 |
| Oda, S | 1 |
| Maehara, Y | 1 |
| Sugimachi, K | 2 |
| Rubiales, AS | 1 |
| del Valle, ML | 1 |
| Schilling, G | 1 |
| Lipp, R | 1 |
| Hegewisch-Becker, S | 1 |
| Hossfeld, DK | 1 |
| Yoon, SY | 1 |
| Mok, YJ | 1 |
| Kim, CS | 1 |
| Hyun, JH | 1 |
| Reimer, P | 1 |
| Rückle-Lanz, H | 1 |
| Basaki, Y | 1 |
| Chikahisa, L | 1 |
| Aoyagi, K | 1 |
| Miyadera, K | 1 |
| Yonekura, K | 1 |
| Hashimoto, A | 1 |
| Okabe, S | 1 |
| Wierzba, K | 1 |
| Yamada, Y | 1 |
| Garibjanian, BT | 1 |
| Johnson, RK | 1 |
| Kline, I | 1 |
| Vadlamudi, S | 1 |
| Gang, M | 1 |
| Venditti, JM | 1 |
| Goldin, A | 1 |
| Nishioka, A | 1 |
| Ogawa, Y | 1 |
| Hamada, N | 1 |
| Terashima, M | 1 |
| Sawada, A | 1 |
| Tanaka, Y | 1 |
| Ogoshi, S | 1 |
| Moreira, LF | 1 |
| Iwagaki, H | 1 |
| Hizuta, A | 1 |
| Sakagami, K | 1 |
| Mimura, H | 1 |
| Orita, K | 1 |
| Ushio, Y | 1 |
| Arita, N | 1 |
| Hayakawa, T | 1 |
| Mogami, H | 1 |
| Bitoh, S | 1 |
| Oku, Y | 1 |
| Kanai, N | 1 |
| Kanoh, M | 1 |
| Unda Urzaiz, M | 1 |
| Zubiaur Líbano, C | 1 |
| Pérez Fernández, A | 1 |
| Iriarte Soldevilla, JI | 1 |
| Flores Corral, N | 1 |
| Korenaga, D | 1 |
| Baba, H | 1 |
| Saito, A | 1 |
| Vachalovský, V | 1 |
| Vomácka, V | 1 |
| Kikuchi, Y | 1 |
| Oomori, K | 1 |
| Iwano, I | 1 |
| Kizawa, I | 1 |
| Miyauchi, M | 1 |
| Kita, T | 1 |
| Kuki, E | 1 |
| Treat, J | 1 |
| Falchuk, SC | 1 |
| Woolley, PV | 1 |
| Ahlgren, JD | 1 |
| Neefe, JR | 1 |
| Smith, FP | 1 |
| Macdonald, JS | 1 |
| Schein, PS | 1 |
| Matsumoto, S | 1 |
| Kutsuna, T | 1 |
| Tann, M | 1 |
| Mizuno, Y | 1 |
| Shinohara, M | 1 |
| Banno, T | 1 |
| Yoshizaki, S | 1 |
| Sugawa, T | 1 |
| Yamagata, S | 1 |
| Koyama, S | 1 |
| Ozaki, A | 1 |
| Iwasaki, Y | 1 |
| Sakita, T | 1 |
| Osuga, T | 1 |
| Watanabe, A | 1 |
| Kawasaki, T | 1 |
| Soma, T | 1 |
| Tabuchi, T | 1 |
| Ohganè, T | 1 |
| Niwa, M | 1 |
| Kure, M | 1 |
| Pasterz, R | 1 |
| Savaraj, N | 1 |
| Burgess, M | 1 |
| Zhero, SV | 1 |
| Ganina, KP | 1 |
| Hanaue, H | 1 |
| Kurosawa, T | 1 |
| Kitano, Y | 1 |
| Miyakawa, S | 1 |
| Nemoto, A | 1 |
| Yamoto, H | 1 |
| Asagoe, T | 1 |
| Shikata, J | 1 |
| Peek, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PD-1 Antibody Plus Gemcitabine and Oxaliplatin (GEMOX) as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma Patients With Positively Metastatic Lymph Nodes : a Single Arm, Phase II Trial[NCT05430698] | Phase 2 | 62 participants (Anticipated) | Interventional | 2023-01-31 | Recruiting | ||
| Phase II Study of S-1 Plus Leucovorin (1 Week on and 1 Week Off) as First-line Treatment for Patients With Metastatic and Recurrent Gastric Cancer[NCT02090153] | Phase 2 | 39 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer[NCT03517618] | Phase 2 | 41 participants (Actual) | Interventional | 2014-07-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for tegafur and Carcinoma, Anaplastic
| Article | Year |
|---|---|
[An autopsy of G-CSF-producing anaplastic carcinoma of the pancreas with impaired accumulation on FDG-PET after S-1 chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Autopsy; Carcinoma; Drug Combinations; Fatal Outcome; Female; | 2013 |
Autopsy of anaplastic carcinoma of the pancreas producing granulocyte colony-stimulating factor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Biopsy; Carcinoma; Deoxycytidine; Drug Comb | 2016 |
[A very elderly case of advanced gastric cancer with disseminated carcinomatosis of bone marrow and multiple bone metastasis, diagnosed by extremely elevated serum alkaline phosphatase levels, and treated with low-dose S-1 to avoid disseminated intravascu
Topics: Aged, 80 and over; Alkaline Phosphatase; Antimetabolites, Antineoplastic; Bone Marrow Neoplasms; Bon | 2011 |
[New therapeutic options in chemotherapy of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Clinical Tria | 2001 |
27 trials available for tegafur and Carcinoma, Anaplastic
| Article | Year |
|---|---|
A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Cisplatin; Drug Combinat | 2013 |
Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2015 |
Phase I Clinical Study of Irinotecan Plus S-1 in Patients With Advanced or Recurrent Cervical Cancer Previously Treated With Platinum-Based Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ca | 2016 |
Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvan | 2016 |
A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; C | 2008 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colore | 2010 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colore | 2010 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colore | 2010 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colore | 2010 |
Phase I study of S-1 plus nedaplatin in patients with advanced/recurrent head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin | 2010 |
Combination therapy with lentinan improves outcomes in patients with esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Cytokines; Drug Therapy, Combination; Esophageal Neop | 2012 |
Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplasti | 2012 |
Concurrent chemoradiotherapy for locally advanced and metastatic esophageal cancer: longterm results of a phase II study of UFT/CDDP with radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combi | 2003 |
Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 2004 |
A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Dose-Res | 2007 |
A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method.
Topics: Administration, Oral; Adult; Aged; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Combi | 2007 |
Phase I dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Docetaxel; Dose-Response Rel | 2009 |
Phase II trial of Oral UFT and leucovorin in advanced gastric carcinoma.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineop | 1996 |
A randomized trial comparing ftorafur alone with ftorafur plus tamoxifen in postoperative adjuvant therapy for breast cancer. Kinki Area Research Group for Postoperative Adjuvant Therapy for Breast Cancer.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Female; Humans; Middle Aged; Su | 1996 |
Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Anemia; Antidotes; Antimetabolites, Antineoplast | 1996 |
Phase II study of UFT plus leucovorin in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Drug Combinations; | 1997 |
A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Diarrhea; Drug Co | 1997 |
Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Coloni | 1998 |
Protracted treatment with tegafur and low dose oral leucovorin in patients with advanced colorectal carcinoma.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Colorectal | 1998 |
UFT/leucovorin plus weekly irinotecan in advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2000 |
Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cispla | 2001 |
Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma; Carcinom | 1991 |
[Adriamycin versus ftorafur in the prevention of recurrence of superficial carcinoma of the bladder].
Topics: Carcinoma; Doxorubicin; Drug Evaluation; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Prosp | 1990 |
[Orimeten in the treatment of advanced carcinoma of the prostate].
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Agents; Carcinoma; Cyclophosphamide; Drug | 1989 |
Randomized controlled study of postoperative adjuvant immunochemotherapy with Nocardia rubra cell wall skeleton (N-CWS) and Tegafur for gastric carcinoma.
Topics: Actuarial Analysis; Adjuvants, Immunologic; Aged; Carcinoma; Cell Wall; Clinical Trials as Topic; Fe | 1986 |
58 other studies available for tegafur and Carcinoma, Anaplastic
| Article | Year |
|---|---|
A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Bile Duct Neoplasms; Carcino | 2020 |
Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycyti | 2020 |
Carcinosarcoma and sarcomatoid carcinoma of the stomach: Two case reports.
Topics: Abdominal Pain; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinosarcoma; Che | 2021 |
[Pulmonary Metastasis of Gastric Cancer as Carcinomatous Lymphangiosis at Five and Half Years after Surgery;Report of a Case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Doc | 2018 |
The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemother | 2014 |
Adjuvant chemotherapy with S-1 followed by docetaxel for gastric cancer and CY1P0 peritoneal metastasis after relatively curative surgery.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy | 2013 |
[A case of gastric cancer accompanied by disseminated carcinomatosis of the bone marrow successfully controlled by S-1 and cisplatin combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carcinoma; Cisplatin; D | 2013 |
Metastatic cutaneous apocrine carcinoma of the axilla successfully treated using systemic chemotherapy with i.v. epirubicin and cyclophosphamide followed by oral fluorinated pyrimidine.
Topics: Adult; Antineoplastic Agents; Axilla; Carcinoma; Cyclophosphamide; Drug Combinations; Epirubicin; Hu | 2014 |
Radiotherapy concurrent with S-1 and radiotherapy alone for T2N0 glottic carcinoma: a retrospective comparative study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Chemoradiotherapy; Drug Combina | 2014 |
[Case report of a patient with advanced and disseminated gastric carcinoma treated by s-1].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2014 |
Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Disease Progression; Drug Combinations; Fem | 2014 |
Is pancreatic fistula associated with worse overall survival in patients with pancreatic carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemother | 2015 |
[A case of anaplastic carcinoma of thyroid administered peroral fluorinated pyrimidine for long-term survival during three years].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2009 |
[A case of inflammatory carcinoma, well-controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2009 |
Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma; Chemotherapy, Adjuvant; D | 2009 |
[A case of advanced gastric cancer with disseminated carcinomatosis of bone marrow treated by S-1 and CDDP].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2009 |
Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2010 |
A quantitative evaluation of the determinant proteins for S-1 responsiveness in a biopsy specimen assists in patient selection to neoadjuvant therapy in cases of advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmaco | 2010 |
Usefulness of interim FDG-PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving sequential induction chemotherapy followed by concurrent chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Ci | 2011 |
S-1 is an active anticancer agent for advanced thymic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma; Disease Progression; Disease-Free Survival; Drug C | 2010 |
[A case of advanced gastric cancer resistant to S-1 successfully treated with weekly administration of paclitaxel].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma; Drug | 2010 |
Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2012 |
Prognostic significance of telomerase activity and human telomerase reverse transcriptase expression in ampullary carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Agents; Biomarkers, Tumor; Carcinom | 2012 |
[A case of disseminated carcinomatosis of bone marrow treated by S-1 and cisplatin after distal gastrectomy for early gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carcinoma; Cisplatin; Dissemi | 2012 |
Chemosensitivity of peritoneal micrometastases as evaluated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Ascites; Carcinoma; Cell Count; Dose | 2003 |
[A case of gastric cancer with metastasis to cervical lymph nodes and pulmonary lymphangitis carcinomatosa responding to neoadjuvant chemotherapy with TS-1 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Combinations; Gastrectomy | 2003 |
[A case of advanced gastric carcinoma successfully treated with TS-1/CDDP as a neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; | 2003 |
Modified pharmacokinetic modulating chemotherapy using 5-fluorouracil, UFT, and taxotere (docetaxel) for advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Docetaxel; Fluorouracil; Humans; Infusion | 2003 |
Oral tegafur/folinic acid chemotherapy decreases phenytoin efficacy.
Topics: Administration, Oral; Anticonvulsants; Antimetabolites, Antineoplastic; Carcinoma; Drug Interactions | 2004 |
[A case of huge submandibular malignant tumor treated successfully with UFT chemotherapy].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Drug Admini | 2004 |
Long-term remission in a patient with carcinoma of unknown primary site.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; Doxorubicin; | 2006 |
[Clinical efficacy of biweekly paclitaxel and S-1 regimen for 14 gastric cancer patients with liver metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Administration Schedule; Drug | 2007 |
[Effects of 5'-deoxy-5-fluorouridine on human gastrointestinal and breast cancers xenografted to nude mice].
Topics: Adenocarcinoma; Administration, Oral; Animals; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Femal | 1984 |
Late results of postoperative long-term cancer chemotherapy for the gastric cancer patients subjected to curative resection.
Topics: Antibiotics, Antineoplastic; Carcinoma; Dose-Response Relationship, Drug; Drug Administration Schedu | 1983 |
Combination chemoimmunotherapy for advanced gastric carcinoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Ca | 1984 |
[Surgical method and combination chemotherapy in treating stage-III and IV ovarian cancer].
Topics: Altretamine; Antineoplastic Agents; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Evaluati | 1980 |
Chemoprevention of development of colonic adenomatosis and carcinomatosis with 5-fluorouracil and ftorafur on animal model.
Topics: Adenoma; Animals; Carcinoma; Colon; Colonic Neoplasms; Female; Fluorouracil; Methylnitrosourea; Neop | 1980 |
Antitumor activity of methyl (5-fluoro-1H-2-oxo-4-pyrimidinyl beta-D-glucopyranosid)uronate against various experimental tumors.
Topics: Animals; Antineoplastic Agents; Carcinoma; Carcinoma 256, Walker; Female; Fluorouracil; Lung Neoplas | 1981 |
[Conservative treatment of primary and recurrent malignant stomach neoplasms].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male | 1981 |
5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Topics: Animals; Carcinoma; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Synergism; Enzyme | 1995 |
Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Antidotes; Antimetabolites, Antineop | 1997 |
Induction of apoptosis in human tumour xenografts after oral administration of uracil and tegafur to nude mice bearing tumours.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Cell Division; Colonic Neoplasms; Ga | 1998 |
Protracted treatment with tegafur and low dose oral leucovorin in patients with advanced colorectal carcinoma.
Topics: Administration, Oral; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Clinical Trials as Topi | 1999 |
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Carc | 2001 |
Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
Topics: Animals; Carcinoma; Cell Line; Drug Resistance; Drug Therapy, Combination; Female; Fluorouracil; Leu | 1976 |
[A case report of bone metastasis diagnosed by MRI and effectively treated with UFT after breast conserving therapy for breast cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast N | 1992 |
Can cytokines prolong survival in ampullary neuroendocrine carcinomas?
Topics: Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Thera | 1992 |
Postoperative adjuvant chemotherapy inhibits early recurrence of early gastric carcinoma.
Topics: Carcinoma; Combined Modality Therapy; Drug Evaluation; Gastrectomy; Humans; Lymphatic Metastasis; Mi | 1989 |
Adjuvant effects of calmodulin antagonists on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur) and a mixture of ftorafur and uracil (UFT) in nude mice bearing human ovarian carcinomas.
Topics: Animals; Calmodulin; Carcinoma; Drug Combinations; Drug Synergism; Female; Fluorouracil; Mice; Mice, | 1989 |
Therapy of advanced gastric carcinoma. The Georgetown-Lombardi Cancer Center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxorubicin; Fluo | 1989 |
[Mammary gland carcinoma treated by large-dose medroxyprogesterone acetate of which pulmonary metastases disappeared and a selection of hormone, chemoimmunological treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined Modality Thera | 1989 |
Reversible leukoencephalopathy caused by 5-fluorouracil derivatives, presenting as akinetic mutism.
Topics: Anal Gland Neoplasms; Animals; Breast Neoplasms; Carcinoma; Female; Fluorouracil; Humans; Leukoencep | 1986 |
[Differing progress patterns in cancer of the uterine cervix and variant effects of adjuvant chemotherapy based on histological type].
Topics: Adenocarcinoma; Azirines; Carbazilquinone; Carcinoma; Carcinoma, Squamous Cell; Female; Humans; Lymp | 1986 |
[Complete remission in a case of concurrent breast and thyroid cancers with metastatic spinal paralysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Female; Humans; Middle | 1986 |
Prognostic factors in metastatic carcinoma of unknown primary.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; | 1986 |
[Determination of the individual sensitivity of human stomach cancer cells to fluoropyrimidines by the cytomorphological criteria of heterotransplants in diffusion chambers].
Topics: Adenocarcinoma; Animals; Carcinoma; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Fe | 1986 |
[Drug distribution to lymph and blood in adjuvant chemotherapy with combined preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil after surgery in gastric cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Humans; Lymph; | 1987 |
[Inflammatory breast carcinoma--possibilities and results of surgical treatment and adjuvant chemotherapy, especially when done preoperatively].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Doxor | 1988 |